zanthoxylum nitidum tincture

PreclinicalSmall molecule

GGuangzhou University of Traditional Chinese Medicine

zanthoxylum nitidum tincture is one of 5 small molecule programs targeting Paronychia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ParonychiaActive, not recruiting

ParonychiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Paronychia

#DrugCompanyPhaseTrials

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

1 2

Betamethasone Valerate

GSK

Phase 3

1 3

Intralesional Steroid

KKasr El Aini Hospital

Phase 3

1 4

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

1 5

zanthoxylum nitidum tincture

GGuangzhou University of Traditional Chinese Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Paronychia1 trial

Effect of Zanthoxylum Nitidum Tincture for Paronychia Caused by Afatinib

Unknown status·GGuangzhou University of Traditional Chinese Medicine·N/A·NCT03908892·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for zanthoxylum nitidum tincture. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — zanthoxylum nitidum tincture compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for zanthoxylum nitidum tincture. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangzhou University of Traditional Chinese Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGuangzhou University of Traditional Chinese Medicine

zanthoxylum nitidum tincture

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Paronychia1 trial

References

Drug Info

Quick Facts

Related News